Europe Active Pharmaceutical Ingredients (API) Market 2021-2027 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application

PrintEmail
Feb 2021 - 167 Pages - From $2,480
(Excel Data Sheet: $1,500)
Description

The report cover may be different from the image shown.

  • The product will be delivered as a PDF file by Email within 48 business hours upon receiving an order. 
  • To learn more about the report, please Download Free Sample Pages and Download Excel Datasheet SampleThe report will be updated before delivery, so that the most recent historic year is the base year and forecast covers 5-10 years over the base year.
  • PleaseContact Us for any question, custom research, and current discount. It is possible now to buy a part of the report such as chapters, sections, data tables or figures.
Product and Price

By clicking the Add to Shopping Cart button, you certify to agree with our Terms of Service.

Europe active pharmaceutical ingredients (API) market accounted for $45.77 billion in 2020 and will grow by 7.5% annually over 2020-2027 the rising need for medicine and pharmaceutical agents amid the COVID-19 pandemic.
Highlighted with 100 tables and 69 figures, this 167-page report “Europe Active Pharmaceutical Ingredients (API) Market 2021-2027 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2020 and provides forecast from 2021 till 2027 with 2020 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.

Based on Synthesis, the Europe market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
Synthetic API
• Branded Synthetic API
• Generic Synthetic API
Biotech API by Drug Type:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biotech APIs
Biotech API by Customer Base:
• Innovative Biologic API
• Generic Biosimilar API
Biotech API by Expression Technology:
• Mammalian Expression
• Microbial Expression
• Yeast Expression
• Insect Expression
• Other Expression Technologies
HPAPI
• Branded HPAPI
• Generic HPAPI

Based on Manufacturing Process, the Europe market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
Captive Manufacturing
• Branded Captive API
• Generic Captive API
Merchant Manufacturing by Drug Type:
• Branded Merchant API
• Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
• Merchant Synthetic API
• Merchant Biotech API

Based on Therapeutic Application, the Europe market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications

Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs

Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue are available for 2017-2027. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe API market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 16
1.2.6 Market Size/Share Estimation 17
1.2.7 Research Limitations 18
1.3 Executive Summary 19
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter’s Fiver Forces Analysis 39
3 Segmentation of Europe Market by Synthesis 43
3.1 Market Overview by Synthesis 43
3.2 Synthetic API 45
3.2.1 Branded Synthetic API 46
3.2.2 Generic Synthetic API 47
3.3 Biotech API 48
3.3.1 Biotech API by Drug Type 49
3.3.1.1 Monoclonal Antibodies 50
3.3.1.2 Recombinant Proteins 51
3.3.1.3 Vaccines 52
3.3.1.4 Other Biotech APIs 53
3.3.2 Biotech API by Customer Base 54
3.3.2.1 Innovative Biologic API 55
3.3.2.2 Generic Biosimilar API 56
3.3.3 Biotech API by Expression Technology 57
3.3.3.1 Mammalian Expression 58
3.3.3.2 Microbial Expression 59
3.3.3.3 Yeast Expression 60
3.3.3.4 Insect Expression 61
3.3.3.5 Other Expression Technologies 62
3.4 HPAPI 63
3.4.1 Branded HPAPI 64
3.4.2 Generic HPAPI 65
4 Segmentation of Europe Market by Manufacturing Process 66
4.1 Market Overview by Manufacturing Process 66
4.2 Captive Manufacturing 68
4.2.1 Branded Captive API 69
4.2.2 Generic Captive API 70
4.3 Merchant Manufacturing 71
4.3.1 Merchant Manufacturing by Drug Type 72
4.3.1.1 Branded Merchant API 73
4.3.1.2 Generic Merchant API 74
4.3.2 Merchant Manufacturing by Drug Synthesis 75
4.3.2.1 Merchant Synthetic API 76
4.3.2.2 Merchant Biotech API 77
5 Segmentation of Europe Market by Therapeutic Application 78
5.1 Market Overview by Therapeutic Application 78
5.2 Infectious Diseases 80
5.3 Oncology 81
5.4 Ophthalmology 82
5.5 Cardiovascular Disorders 83
5.6 Central Nervous System 84
5.7 Pulmonary Disorders 85
5.8 Orthopedics 86
5.9 Other Applications 87
6 Segmentation of Europe Market by Drug Type 88
6.1 Market Overview by Drug Type 88
6.2 Branded Prescription Drugs 90
6.3 Generic Prescription Drugs 91
6.4 OTC Drugs 92
7 European Market 2020-2027 by Country 93
7.1 Overview of European Market 93
7.2 UK 96
7.3 France 98
7.4 Germany 100
7.5 Spain 102
7.6 Italy 104
7.7 Russia 106
7.8 Rest of European Market 108
8 Competitive Landscape 110
8.1 Overview of Key Vendors 110
8.2 New Product Launch, Partnership, Investment, and M&A 113
8.3 Company Profiles 114
AbbVie Inc. 114
Astrazeneca 116
Aurobindo Pharma Ltd. 119
BASF 121
Bayer AG 124
Boehringer Ingelheim 126
Dr. Reddy's Laboratories 130
F. Hoffmann-La Roche 132
GlaxoSmithKline plc 134
Lonza Group 138
Lupin Limited 142
Merck & Co., Inc. 144
Mylan NV 146
Novartis International AG 148
Pfizer Inc. 150
Sanofi 154
Sun Pharmaceutical Industries Ltd. 156
Teva Pharmaceutical Industries Ltd. 158
9 Investing in Europe Market: Risk Assessment and Management 161
9.1 Risk Evaluation of Europe Market 161
9.2 Critical Success Factors (CSFs) 164
Related Reports and Products 167

List of Tables:

Table 1. Snapshot of Europe Active Pharmaceutical Ingredients (API) Market in Balanced Perspective, 2020-2027 20
Table 2. Growth Rate of World Real GDP, 2017-2021 23
Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 31
Table 4. Main Product Trends and Market Opportunities in Europe Active Pharmaceutical Ingredients (API) Market 35
Table 5. Europe Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 43
Table 6. Europe Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2017-2027, $ bn 45
Table 7. Europe Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2017-2027, $ bn 49
Table 8. Europe Active Pharmaceutical Ingredients (API) Market: Biotech API by Customer Base, 2017-2027, $ bn 54
Table 9. Europe Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2017-2027, $ bn 57
Table 10. Europe Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2017-2027, $ bn 63
Table 11. Europe Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 66
Table 12. Europe Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2017-2027, $ bn 68
Table 13. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2017-2027, $ bn 72
Table 14. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2017-2027, $ bn 75
Table 15. Europe Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 78
Table 16. Europe Active Pharmaceutical Ingredients (API) Market by Drug Type, 2017-2027, $ bn 88
Table 17. Europe Active Pharmaceutical Ingredients (API) Market by Country, 2017-2027, $ bn 95
Table 18. UK Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 97
Table 19. UK Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 97
Table 20. UK Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 97
Table 21. France Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 99
Table 22. France Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 99
Table 23. France Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 99
Table 24. Germany Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 101
Table 25. Germany Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 101
Table 26. Germany Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 101
Table 27. Spain Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 103
Table 28. Spain Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 103
Table 29. Spain Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 103
Table 30. Italy Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 105
Table 31. Italy Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 105
Table 32. Italy Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 105
Table 33. Russia Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 107
Table 34. Russia Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 107
Table 35. Russia Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 107
Table 36. Active Pharmaceutical Ingredients (API) Market in Rest of Europe by Country, 2017-2027, $ bn 109
Table 37. AbbVie Inc.: Company Snapshot 114
Table 38. AbbVie Inc.: Product Portfolio 114
Table 39. AbbVie Inc.: Revenue, 2017-2019, $ bn 115
Table 40. Astrazeneca: Company Snapshot 116
Table 41. Astrazeneca: Revenue, 2017-2019, $ bn 117
Table 42. Aurobindo Pharma Ltd.: Company Snapshot 119
Table 43. Aurobindo Pharma Ltd.: Product Portfolio 120
Table 44. Aurobindo Pharma Ltd.: Revenue, 2016-2020, $ INR million 120
Table 45. BASF: Company Snapshot 121
Table 46. BASF: Business Segmentation 122
Table 47. BASF: Revenue, 2016-2018, Euro million 122
Table 48. Bayer AG: Company Snapshot 124
Table 49. Bayer AG: Business Segmentation 125
Table 50. Bayer AG: Revenue, 2016-2018, € bn 125
Table 51. Bayer AG: Recent Developments 125
Table 52. Boehringer Ingelheim: Company Snapshot 126
Table 53. Boehringer Ingelheim: Business Segmentation in 2019 127
Table 54. Boehringer Ingelheim: Product Portfolio 127
Table 55. Boehringer Ingelheim: Revenue, 2017-2019, EUR million 128
Table 56. Boehringer Ingelheim: Revenue by Region in 2019 128
Table 57. Boehringer Ingelheim: Recent Developments 128
Table 58. Dr. Reddy's Laboratories: Company Snapshot 130
Table 59. Dr. Reddy's Laboratories: Business Segmentation 130
Table 60. Dr. Reddy's Laboratories: Revenue, 2018-2020, $ bn 131
Table 61. F. Hoffmann-La Roche: Company Snapshot 132
Table 62. AbbVie Inc.: Business Segmentation 132
Table 63. F. Hoffmann-La Roche: Revenue, 2017-2019, $ bn 133
Table 64. GlaxoSmithKline: Company Snapshot 134
Table 65. GlaxoSmithKline: Business Segmentation 135
Table 66. GlaxoSmithKline: Product Portfolio 136
Table 67. GlaxoSmithKline: Revenue, 2016-2018, $ bn 137
Table 68. GlaxoSmithKline: Recent Developments 137
Table 69. Lonza Group: Company Snapshot 138
Table 70. Lonza Group: Business Segmentation in 2018 139
Table 71. Lonza Group: Product Portfolio 139
Table 72. Lonza Group: Revenue, 2017-2019, $ billion 140
Table 73. Lonza Group: Revenue by Region in 2018 140
Table 74. Lonza Group: Recent Developments 141
Table 75. Lupin Limited: Company Snapshot 142
Table 76. Lupin Limited: Business Segmentation 142
Table 77. Lupin Limited: Revenue, 2016-2018, INR billion 143
Table 78. Merck & Co., Inc.: Company Snapshot 144
Table 79. Merck & Co., Inc.: Business Segmentation 144
Table 80. Merck & Co., Inc.: Revenue, 2017-2019, $ bn 145
Table 81. Mylan NV: Company Snapshot 146
Table 82. Mylan NV: Revenue, 2017-2019, $ bn 147
Table 83. Novartis International AG: Company Snapshot 148
Table 84. Novartis International AG: Business Segmentation 148
Table 85. Novartis International AG: Revenue, 2017-2019, $ bn 149
Table 86. Pfizer Inc.: Company Snapshot 150
Table 87. Pfizer Inc.: Business Segmentation 151
Table 88. Pfizer Inc.: Product Portfolio 151
Table 89. Pfizer Inc.: Revenue, 2016-2018, $ bn 152
Table 90. Pfizer Inc.: Recent Developments 152
Table 91. Sanofi: Company Snapshot 154
Table 92. Sanofi: Business Segmentation 154
Table 93. Sanofi: Revenue, 2017-2019, $ bn 155
Table 94. Sun Pharmaceutical Industries Limited: Company Snapshot 156
Table 95. Sun Pharmaceutical Industries Limited: Revenue, 2017-2019, INR bn 157
Table 96. Teva Pharmaceutical Industries Ltd.: Company Snapshot 158
Table 97. Teva Pharmaceutical Industries Ltd.: Business Segmentation 159
Table 98. Teva Pharmaceutical Industries Ltd.: Revenue, 2017-2019, $ bn 159
Table 99. Risk Evaluation for Investing in Europe Market, 2020-2027 162
Table 100. Critical Success Factors and Key Takeaways 165

 

 

List of Figures:

Figure 1. Research Method Flow Chart 13
Figure 2. Breakdown of Primary Research 15
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 17
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 19
Figure 5. Europe Active Pharmaceutical Ingredients (API) Market, 2020-2027, $ bn 21
Figure 6. Impact of COVID-19 on Business 25
Figure 7. Primary Drivers and Impact Factors of Europe Active Pharmaceutical Ingredients (API) Market 27
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 30
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 10. Primary Restraints and Impact Factors of Europe Active Pharmaceutical Ingredients (API) Market 32
Figure 11. Investment Opportunity Analysis 36
Figure 12. Porter’s Fiver Forces Analysis of Europe Active Pharmaceutical Ingredients (API) Market 39
Figure 13. Breakdown of Europe Active Pharmaceutical Ingredients (API) Market by Synthesis, 2020-2027, % of Revenue 43
Figure 14. Contribution to Europe 2021-2027 Cumulative Revenue by Synthesis, Value ($ bn) and Share (%) 44
Figure 15. Europe Active Pharmaceutical Ingredients (API) Market: Synthetic API, 2017-2027, $ bn 45
Figure 16. Europe Active Pharmaceutical Ingredients (API) Market: Branded Synthetic API, 2017-2027, $ bn 46
Figure 17. Europe Active Pharmaceutical Ingredients (API) Market: Generic Synthetic API, 2017-2027, $ bn 47
Figure 18. Europe Active Pharmaceutical Ingredients (API) Market: Biotech API, 2017-2027, $ bn 48
Figure 19. Europe Active Pharmaceutical Ingredients (API) Market: Monoclonal Antibodies, 2017-2027, $ bn 50
Figure 20. Europe Active Pharmaceutical Ingredients (API) Market: Recombinant Proteins, 2017-2027, $ bn 51
Figure 21. Europe Active Pharmaceutical Ingredients (API) Market: Vaccines, 2017-2027, $ bn 52
Figure 22. Europe Active Pharmaceutical Ingredients (API) Market: Other Biotech APIs, 2017-2027, $ bn 53
Figure 23. Europe Active Pharmaceutical Ingredients (API) Market: Innovative Biologic API, 2017-2027, $ bn 55
Figure 24. Europe Active Pharmaceutical Ingredients (API) Market: Generic Biosimilar API, 2017-2027, $ bn 56
Figure 25. Europe Active Pharmaceutical Ingredients (API) Market: Mammalian Expression, 2017-2027, $ bn 58
Figure 26. Europe Active Pharmaceutical Ingredients (API) Market: Microbial Expression, 2017-2027, $ bn 59
Figure 27. Europe Active Pharmaceutical Ingredients (API) Market: Yeast Expression, 2017-2027, $ bn 60
Figure 28. Europe Active Pharmaceutical Ingredients (API) Market: Insect Expression, 2017-2027, $ bn 61
Figure 29. Europe Active Pharmaceutical Ingredients (API) Market: Other Expression Technologies, 2017-2027, $ bn 62
Figure 30. Europe Active Pharmaceutical Ingredients (API) Market: HPAPI, 2017-2027, $ bn 63
Figure 31. Europe Active Pharmaceutical Ingredients (API) Market: Branded HPAPI, 2017-2027, $ bn 64
Figure 32. Europe Active Pharmaceutical Ingredients (API) Market: Generic HPAPI, 2017-2027, $ bn 65
Figure 33. Breakdown of Europe Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2020-2027, % of Revenue 66
Figure 34. Contribution to Europe 2021-2027 Cumulative Revenue by Manufacturing Process, Value ($ bn) and Share (%) 67
Figure 35. Europe Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing, 2017-2027, $ bn 68
Figure 36. Europe Active Pharmaceutical Ingredients (API) Market: Branded Captive API, 2017-2027, $ bn 69
Figure 37. Europe Active Pharmaceutical Ingredients (API) Market: Generic Captive API, 2017-2027, $ bn 70
Figure 38. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing, 2017-2027, $ bn 71
Figure 39. Europe Active Pharmaceutical Ingredients (API) Market: Branded Merchant API, 2017-2027, $ bn 73
Figure 40. Europe Active Pharmaceutical Ingredients (API) Market: Generic Merchant API, 2017-2027, $ bn 74
Figure 41. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Synthetic API, 2017-2027, $ bn 76
Figure 42. Europe Active Pharmaceutical Ingredients (API) Market: Merchant Biotech API, 2017-2027, $ bn 77
Figure 43. Breakdown of Europe Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2020-2027, % of Revenue 78
Figure 44. Contribution to Europe 2021-2027 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 79
Figure 45. Europe Active Pharmaceutical Ingredients (API) Market: Infectious Diseases, 2017-2027, $ bn 80
Figure 46. Europe Active Pharmaceutical Ingredients (API) Market: Oncology, 2017-2027, $ bn 81
Figure 47. Europe Active Pharmaceutical Ingredients (API) Market: Ophthalmology , 2017-2027, $ bn 82
Figure 48. Europe Active Pharmaceutical Ingredients (API) Market: Cardiovascular Disorders, 2017-2027, $ bn 83
Figure 49. Europe Active Pharmaceutical Ingredients (API) Market: Central Nervous System, 2017-2027, $ bn 84
Figure 50. Europe Active Pharmaceutical Ingredients (API) Market: Pulmonary Disorders, 2017-2027, $ bn 85
Figure 51. Europe Active Pharmaceutical Ingredients (API) Market: Orthopedics, 2017-2027, $ bn 86
Figure 52. Europe Active Pharmaceutical Ingredients (API) Market: Other Applications, 2017-2027, $ bn 87
Figure 53. Breakdown of Europe Active Pharmaceutical Ingredients (API) Market by Drug Type, 2020-2027, % of Revenue 88
Figure 54. Contribution to Europe 2021-2027 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 89
Figure 55. Europe Active Pharmaceutical Ingredients (API) Market: Branded Prescription Drugs, 2017-2027, $ bn 90
Figure 56. Europe Active Pharmaceutical Ingredients (API) Market: Generic Prescription Drugs, 2017-2027, $ bn 91
Figure 57. Europe Active Pharmaceutical Ingredients (API) Market: OTC Drugs, 2017-2027, $ bn 92
Figure 58. European Active Pharmaceutical Ingredients (API) Market, 2017-2027, $ bn 94
Figure 59. Breakdown of European Active Pharmaceutical Ingredients (API) Market by Country, 2020 and 2027, % of Revenue 94
Figure 60. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 95
Figure 61. Active Pharmaceutical Ingredients (API) Market in UK, 2017-2027, $ bn 96
Figure 62. Active Pharmaceutical Ingredients (API) Market in France, 2017-2027, $ bn 98
Figure 63. Active Pharmaceutical Ingredients (API) Market in Germany, 2017-2027, $ bn 100
Figure 64. Active Pharmaceutical Ingredients (API) Market in Spain, 2017-2027, $ bn 102
Figure 65. Active Pharmaceutical Ingredients (API) Market in Italy, 2017-2027, $ bn 104
Figure 66. Active Pharmaceutical Ingredients (API) Market in Russia, 2017-2027, $ bn 106
Figure 67. Active Pharmaceutical Ingredients (API) Market in Rest of Europe, 2017-2027, $ bn 108
Figure 68. Growth Stage of Europe Active Pharmaceutical Ingredients (API) Industry over the Forecast Period 110
Figure 69. Top products of AstraZeneca based on revenue from 2016 to 2019 (in million U.S. dollars) 117

 

Reviews

There are yet no reviews for this product.